Teva, Merck agree to 2017 date for Vytorin copies

Teva Pharmaceutical Industries has agreed that it won't sell generic versions of Merck's ($MRK) cholesterol drugs Vytorin and Zetia until 2017, settling patent disputes between the two companies. Merck still faces a patent fight with Mylan over Zetia and Vytorin, however. Report